Université de Fribourg

Amphiphilic nanoparticle delivery enhances the anticancer efficacy of a TLR7 ligand via local immune activation

Mottas, Inès ; Bekdemir, Ahmet ; Cereghetti, Alessandra ; Spagnuolo, Lorenzo ; Yang, Yu-Sang Sabrina ; Müller, Marie ; J.Irvine, Darrell ; Stellaccic, Francesco ; Bourquin, Carole

In: Biomaterials, 2019, vol. 190–191, p. 111–120

Although immunotherapy shows great promise for the long-term control of cancer, many tumors still fail to respond to treatment. To improve the outcome, the delivery of immunostimulants to the lymph nodes draining the tumor, where the antitumor immune response is initiated, is key. Efforts to use nanoparticles as carriers for cancer immunotherapy have generally required targeting agents and...

Université de Fribourg

NAB2 is a novel immune stimulator of MDA-5 that promotes a strong type I interferon response

Oberson, Anne ; Spagnuolo, Lorenzo ; Puddinu, Viola ; Barchet, Winfried ; Rittner, Karola ; Bourquin, Carole

In: Oncotarget, 2018, vol. 9, no. 5, p. -

Novel adjuvants are needed to increase the efficacy of vaccine formulations and immune therapies for cancer and chronic infections. In particular, adjuvants that promote a strong type I IFN response are required, since this cytokine is crucial for the development of efficient anti-tumoral and anti-viral immunity. Nucleic acid band 2 (NAB2) is a double- stranded RNA molecule isolated from...

Université de Fribourg

Arginase inhibition suppresses lung metastasis in the 4T1 breast cancer model independently of the immunomodulatory and anti-metastatic effects of VEGFR-2 blockade

Secondini, Chiara ; Coquoz, Oriana ; Spagnuolo, Lorenzo ; Spinetti, Thibaud ; Peyvandi, Sanam ; Ciarloni, Laura ; Botta, Francesca ; Bourquin, Carole ; Rüegg, Curzio

In: OncoImmunology, 2017, vol. 6, no. 6, p. e1316437

Tumor angiogenesis promotes tumor growth and metastasis. Anti-angiogenic therapy in combination with chemotherapy is used for the treatment of metastatic cancers, including breast cancer but therapeutic benefits are limited. Mobilization and accumulation of myeloid-derived suppressor cells (MDSC) during tumor progression and therapy have been implicated in metastasis formation and resistance to...

Université de Fribourg

TLR7-based cancer immunotherapy decreases intratumoral myeloid-derived suppressor cells and blocks their immunosuppressive function

Spinetti, Thibaud ; Spagnuolo, Lorenzo ; Mottas, Inès ; Secondini, Chiara ; Treinies, Marina ; Rüegg, Curzio ; Hotz, Christian ; Bourquin, Carole

In: OncoImmunology, 2016, vol. 5, no. 11, p. e1230578

Myeloid-derived suppressor cells (MDSC) are a heterogeneous population of immature myeloid cells with the capacity to inhibit immunological responses. During cancer progression, MDSC are recruited to the tumor sites and secondary lymphoid organs, leading to the suppression of the antitumor function of NK and T cells. Here, we show that the TLR7/8 agonist resiquimod (R848) has a direct effect...

Université de Fribourg

Reprogramming of TLR7 signaling enhances antitumor NK and cytotoxic T cell responses

Hotz, Christian ; Treinies, Marina ; Mottas, Ines ; Rötzer, Laurin C. ; Oberson, Anne ; Spagnuolo, Lorenzo ; Perdicchio, Maurizio ; Spinetti, Thibaud ; Herbst, Tina ; Bourquin, Carole

In: OncoImmunology, 2016, vol. 5, no. 11, p. e1232219

Toll-like receptor (TLR) 7 agonists are effective in topical application for the immunotherapy of skin cancers, but their performance for the systemic treatment of solid tumors is limited by the development of TLR tolerance. In this study, we describe a novel strategy to overcome TLR tolerance and enhance TLR7-dependent antitumor immune responses through reprogramming of TLR signaling...